Equity
€190,043 ▲ 42.9%
Equity rose in 2025 from €132,954 to €190,043.
BLSMU
Lifetime
4 annual accounts with figures on one time axispeak €109,122 (2023)
€93,866▼ 0.1%
peak €62,160 (2023)
€57,089▲ 6.4%
peak €190,043 (2025)
€190,043▲ 42.9%
€8,257▼ 26.0%
Board1 name since 2022
1 directorLABOULLE Benjamin Pierre Maggy Barbara
Documentsfilings and deeds
16-03-2026137 days before the deadline
2025micro format
Equity from €132,954 to €190,043Debts from €11,161 to €8,257Investments €7,258Cash from €77,070 to €184,190
Key points
from the 2025 annual accountsTurnover
≈ €210,000 estimated
The micro format states no turnover.
Investments
€7,758 5.2 × depreciation
Green is investment, beige is depreciation.
Liquidity
25.17 was 14.26 in 2024
Short-term debts fell from €11,161 to €8,257.
Filings
4 annual accounts 1 late
The 2022 accounts came 24 days late. The other three were filed on time.
Position in the sector
88.5%
Higher solvency than 81% of companies in human health. Sector median 63.0% · 20,774 companies.
Checked score
97
Excellent
Financially stronger than 75% of micro companies in human health (NACE 86)
Probability in this band: under 0.55%
Bankruptcy probability within 12 months
< 0.1% Very low
0%0.5%1.5%4%10%≥ 25%
The dashed line is the sector median: < 0.1% across 24,192 companies (NACE 86, micro).
Fewer than 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
12-2024: < 0.1%
01-2025: < 0.1%● unchanged vs 12-2024
02-2025: < 0.1%● unchanged vs 01-2025
03-2025: < 0.1%● unchanged vs 02-2025
04-2025: < 0.1%● unchanged vs 03-2025
05-2025: < 0.1%● unchanged vs 04-2025
06-2025: < 0.1%● unchanged vs 05-2025
07-2025: < 0.1%● unchanged vs 06-2025highest value
08-2025: < 0.1%● unchanged vs 07-2025
09-2025: < 0.1%● unchanged vs 08-2025
10-2025: < 0.1%● unchanged vs 09-2025
11-2025: < 0.1%● unchanged vs 10-2025
12-2025: < 0.1%● unchanged vs 11-2025
01-2026: < 0.1%● unchanged vs 12-2025
02-2026: < 0.1%● unchanged vs 01-2026
03-2026: < 0.1%● unchanged vs 02-2026
04-2026: < 0.1%● unchanged vs 03-2026lowest value
05-2026: < 0.1%● unchanged vs 04-2026lowest value
06-2026: < 0.1%● unchanged vs 05-2026
07-2026: < 0.1%● unchanged vs 06-2026
08-2026: < 0.1%● unchanged vs 07-2026
09-2026: < 0.1%● unchanged vs 08-2026
10-2026: < 0.1%● unchanged vs 09-2026
11-2026: < 0.1%● unchanged vs 10-2026
Financial strengthStrong
Score breakdown
raises risk
1 change of registered office in 24 months
lowers risk
Liquidity: current ratio 25.17, cash €184,190
Sector: Human health activities (NACE 86)
Equity €190,043 (88.5% of total assets)
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 86, micro). It does better than 82% of them on solvency, 95% on liquidity, 46% on profitability and 78% on growth.
The bankruptcy probability was computed on 10-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
The probability rests on the annual accounts with balance sheet date 31-12-2025.
Of the companies with a bankruptcy probability in the very low class on 30-06-2025, 0.1% went bankrupt within twelve months.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Comparable companies, two years later
In July 2024, 39,278 companies had the same profile as BLSMU has now. Each dot stands for 99 companies, two years later.
95.8%
were still trading
2.3%
stopped another way
1.8%
went bankrupt
Another 0.1% stopped without a precise date, possibly only after those two years.
The bankruptcy probability of BLSMU itself is lower: < 0.1% within 12 months. It rests on far more data about BLSMU than the profile alone.
Test of the method
The method was tested on the 497,448 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 39,278 companies, not a prediction for BLSMU. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit of up to €18,000 on 30-day terms is acceptable
Liquidity is ample, with a current ratio of 25.17 (14.26 in 2024), above the usual 1.5. Short-term debt is 3.8% and cash 85.8% of total assets. 11.5% of the assets are financed with debt and provisions.
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Five signals.
lowers riskraises riskneutral
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 16-03-2026, 137 days ahead of the deadline.
NBB · 4 filingsDeviation from the deadline
2025
137 days early
2024
21 days early
2023
44 days early
2022
24 days late
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
The company filed its last 4 accounts on average 45 days before the deadline. In the sector (NACE 86), the median for financial year 2024 was 7 days before the deadline, and 36% of those companies filed late.
Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 29 June (3 of the last 4 accounts filed within 56 days either side of that date).
Companies Code · seven monthsWhere today falls in the filing period
11-11-2026 today31-12-2026 year end31-07-2027 deadline
Board and ownership
- LABOULLE Benjamin Pierre Maggy Barbara 100 sharesdeed of 05-10-2022
Recent changes
Registered office moved within Chaudfontaine
New registered office: Voie de l'Ardenne 105, 4053 Chaudfontaine · Previous registered office: Rue Paradis des Chevaux 6, 4053 Chaudfontaine · Board meeting of 17-03-2026 · Gazette deed
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0791753095
Incorporation
Founding capital of €2,500, 100 shares · Founder: LABOULLE Benjamin Pierre Maggy Barbara · Appointment: LABOULLE Benjamin Pierre Maggy Barbara (director) · published on 05-10-2022 · Gazette deed
First establishment
Paradis des Chevaux 6, Chaudfontaine
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| BLSMU Chaudfontaine | €214,708 | €93,866 | 88.5% | - |
| LV ENDOCRINE Chaudfontaine | €204,571 | €97,303 | 77.8% | - |
| ThDerm Liège | €206,611 | €103,901 | 15.8% | - |
| Dr. Ellen Veef - Anesthesie Damme | €207,643 | €94,642 | 57.0% | - |
| Geoffrey Horlait Réanimation Floreffe | €221,351 | €97,615 | 83.6% | - |
| DR. ELENA VANKWIKELBERGE - DERMATOLOGIE Nazareth | €236,436 | €93,614 | 89.7% | - |
| N.V. Derm Anderlues | €232,580 | €100,459 | 37.4% | - |
These companies have the same main activity as BLSMU: specialist medical practice (NACE 86220). They are comparable in size and age: total assets between €205,000 and €236,000, founded between 2022 and 2023.
Official details
Source: KBO- Status
- Active since 03-10-2022Normal situation
- Activity
- Specialist medical practiceNACE 86220
- Establishment unit
- 2.336.654.7744053 Chaudfontaine, since 03-10-2022
- Financial year end
- 31 December
- Peppol
- Reachable since 12-10-2025
Annual accounts 2025
- €214,708▲ 34.0%
- Filing
- Filed on 16-03-2026, 137 days before the end of the filing period
Insights on BLSMU
BLSMU files the micro format. That format states no turnover. The gross margin rose from €25,832 in 2022 to €93,866 in 2025.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about BLSMU
- What is the company number of BLSMU?
- The company number of BLSMU is 0791.753.095. The VAT number is the same number with BE in front: BE 0791.753.095.
- Where is BLSMU based?
- The registered office is at Voie de l'Ardenne 105, 4053 Chaudfontaine.Company details
- What does BLSMU do?
- According to the KBO register, the main activity is specialist medical practice (NACE 86220).
- What is the legal form of BLSMU?
- BLSMU is a private limited company (BV).
- When was BLSMU founded?
- BLSMU was founded on 03-10-2022.
- Is BLSMU still active?
- Yes, BLSMU is an active enterprise in the KBO register.
- What is the turnover of BLSMU?
- The turnover in financial year 2025 is ≈ €210,000. This figure is estimated from the gross margin of €93,866 and 32 comparable companies (NACE 862). It probably lies between €160,000 and €270,000.Financials
- Is BLSMU profitable?
- In financial year 2025, BLSMU made a profit of €57,089.
- Where can I find the annual accounts of BLSMU?
- BLSMU filed 4 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of BLSMU due?
- BLSMU must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.